Brokerages Set GSK PLC Sponsored ADR (NYSE:GSK) Price Target at $53.00

GSK PLC Sponsored ADR (NYSE:GSK) has been assigned a consensus recommendation of “Hold” from the ten brokerages that are currently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation, one has given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $53.00.

A number of research analysts recently commented on the stock. HSBC upgraded shares of GSK from a “reduce” rating to a “hold” rating in a research note on Monday, July 6th. Jefferies Financial Group upgraded GSK to a “strong-buy” rating in a research report on Friday, July 17th. Wall Street Zen downgraded GSK from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Citigroup assumed coverage on GSK in a report on Friday, July 24th. They issued a “neutral” rating for the company. Finally, Morgan Stanley reaffirmed an “underweight” rating on shares of GSK in a research note on Tuesday, August 25th.

Institutional Trading of GSK

A number of large investors have recently added to or reduced their stakes in GSK. Corient Private Wealth LP grew its position in GSK by 0.8% in the second quarter. Corient Private Wealth LP now owns 105,377 shares of the pharmaceutical company’s stock worth $5,524,000 after buying an additional 864 shares during the last quarter. Ameritas Advisory Services LLC lifted its position in shares of GSK by 38.8% during the 2nd quarter. Ameritas Advisory Services LLC now owns 12,918 shares of the pharmaceutical company’s stock valued at $677,000 after acquiring an additional 3,611 shares during the last quarter. Figure 8 Investment Strategies LLC boosted its stake in shares of GSK by 90.5% during the 2nd quarter. Figure 8 Investment Strategies LLC now owns 38,686 shares of the pharmaceutical company’s stock worth $2,028,000 after acquiring an additional 18,380 shares in the last quarter. HB Wealth Management LLC grew its holdings in shares of GSK by 7.1% in the 2nd quarter. HB Wealth Management LLC now owns 19,731 shares of the pharmaceutical company’s stock worth $1,034,000 after acquiring an additional 1,310 shares during the last quarter. Finally, Nvest Financial LLC acquired a new position in shares of GSK in the 2nd quarter worth $2,236,000. 15.74% of the stock is currently owned by institutional investors.

GSK Trading Down 1.9%

NYSE:GSK opened at $49.88 on Monday. The stock has a market cap of $100.89 billion, a price-to-earnings ratio of 15.60, a PEG ratio of 1.99 and a beta of 0.35. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.52 and a current ratio of 0.82. GSK has a 1 year low of $39.29 and a 1 year high of $61.69. The business has a fifty day moving average of $51.70 and a 200-day moving average of $53.20.

GSK (NYSE:GSK) last posted its quarterly earnings data on Tuesday, July 28th. The pharmaceutical company reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.27 by $0.09. GSK had a net margin of 14.56% and a return on equity of 43.23%. The business had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.02 billion. During the same quarter in the prior year, the company posted $0.47 earnings per share. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. GSK has set its FY 2026 guidance at 4.900-5.000 EPS. Equities analysts predict that GSK will post 4.82 earnings per share for the current year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 8th. Stockholders of record on Friday, August 14th will be paid a $0.4515 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $1.81 annualized dividend and a dividend yield of 3.6%. This is an increase from GSK’s previous quarterly dividend of $0.44. GSK’s dividend payout ratio is presently 55.31%.

Key GSK News

Here are the key news stories impacting GSK this week:

• Positive Sentiment: GSK agreed to license exclusive rights outside Mainland China, Hong Kong, Macau and Taiwan to Hutchmed’s experimental KRAS-EGFR antibody-drug conjugate, HMPL-A830. The deal includes a reported $110 million upfront payment and could be worth up to $1.295 billion in total milestone payments, giving GSK access to a potentially differentiated solid-tumor treatment. HUTCHMED signs licensing deal with GSK for experimental solid tumour drug
• Positive Sentiment: Deutsche Bank said GSK’s Phase II mRNA flu vaccine results closely track data from Moderna’s comparable candidate. The read-through supports the credibility of GSK’s vaccine platform and could strengthen expectations for a future product in the seasonal influenza market. GSK’s mRNA flu vaccine data closely tracks Moderna’s
• Neutral Sentiment: Coverage also points to solid first-half growth and continued support from the licensing transaction. However, HMPL-A830 is an experimental, early-stage asset, so GSK must fund further development and still faces clinical, regulatory and commercial execution risks before the program can generate revenue. GSK stock gains support from licensing deal and solid first-half growth

About GSK

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.